Dr. Faizi Asim Jamal, MD

Dr. Jamal practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Jamal's NPI, 1538217567, was assigned on January 8, 2007. Dr. Jamal graduated from UC Irvine School of Medicine in 2003. Dr. Jamal holds California license A91207.

Dr. Jamal's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Jamal's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. Dr. Jamal is also affiliated with Huntington Hospital. The medical group on file is City of Hope. Dmand AI also links Dr. Jamal to 2 more hospitals and 1 other site, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jamal practices, 4 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Jamal's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Jamal is board certified in cardiovascular disease by the American Board of Internal Medicine. Dmand AI has Dr. Jamal's licenses on file in 3 states: California, Illinois and Nevada.

Dmand AI lists atrial fibrillation and flutter, cardiomyopathy, chronic hypertension, coronary artery disease, heart failure, heart valve disorders, high cholesterol and intermittent racing heartbeat (PSVT) among the conditions Dr. Jamal treats.

CMS data shows 2,510 Medicare services from Dr. Jamal across 19 procedure codes in 2024, for 1,357 Medicare patients. Medicare paid $70,446 for them.

CMS counts 1,357 Medicare patients who saw Dr. Jamal in 2024. The largest group is 65 to 74, with 670 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 36% are also on Medicaid. Their average risk score is 2.88, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jamal's median patient age at 67, with 55% women.

In 2024, Dr. Jamal wrote 717 Medicare Part D claims for 109 patients. 79% of them were for generic drugs. CMS names the drug for 615 of them, across 19 drugs with 11 or more claims each, at $168,098 in total drug cost. In 2023, CMS named 550 claims across 17 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Jamal for performance year 2024, reported as part of a group. Dr. Jamal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Jamal as offering telehealth.

Dmand AI links 9 papers to Dr. Jamal, published from 2019 to 2024. 2024 was the busiest year, with 2. The most frequent topics are Cardiovascular Diseases, Hematopoietic Stem Cell Transplantation and Coronary Artery Disease. Dr. Jamal has published most often in Curr Hematol Malig Rep. Dr. Jamal's most frequent co-authors are Stephen J. Forman, MD, Saro Haroutume Armenian, MD and Samer K. Khaled, MD.

CMS Open Payments shows 23 general payments to Dr. Jamal from 4 drug and device companies from 2021 to 2025. Consulting fees make up the largest share, 87% of the total. Alnylam Pharmaceuticals Inc. paid the most, $12,325.

Dr. Jamal graduated from UC Irvine School of Medicine in 2003.

Dr. Jamal is in network with 16 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.